• About us
• Contact

Advertisement

Organisation › Details

Business France

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the VIE international internship program. Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 73 countries throughout the world, who work with a network of public- and private-sector partners. *

 

	Start	2015-01-01 merged
	Group	France (govt)
	Predecessor	UBIFRANCE
	Industry	business development (state/region)
	Industry 2	business services
	Person	Pénicaud, Muriel (France (govt) 201601 Head of Business France)
	Region	Paris
	Country	France
	Street	77 boulevard Saint-Jacques
	City	75014 Paris
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Medicen Paris Region. (5/23/17). "Press Release: French Tech Tour Healthcare Israel. Seven Start-ups Assess their Business Potential with Business France, Bpifrance and Medicen Paris Region". Paris.
		Record changed: 2024-02-12

Advertisement

More documents for France (govt)

• [1] SurgeCare SAS. (3/27/24). "Press Release: Surge Announces Closing of a €7.5 Million Fundraising Round to Decrypt the Immune System and Transform Precision Medicine". Paris....
• [2] Global Bioenergies S.A.. (10/4/23). "Press Release: French Government Awards Global Bioenergies €16.4 Million to Help Fund Construction of the World’s First Biosourced Isobutene Plant". Évry....
• [3] EverImmune. (9/19/23). "Press Release: EverImmune Secures €3.5 Million in Financing from Bpifrance". Villejuif....
• [4] Biper Therapeutics SAS. (2/14/23). "Press Release: Biper Therapeutics Raises €1.25 Million in Seed Funding to Develop First-in-Class Small Molecules to Treat Gastrointestinal Cancers". Strasbourg....
• [5] Theranexus S.A.. (10/20/22). "Press Release: Theranexus and Inserm Transfert Sign a Strategic Alliance to Identify Advanced Therapy Drug Candidates for Rare Neurological Diseases". Lyon....
• [6] AdBio Partners SAS. (5/3/22). "Press Release: AdBio Partners Welcomes Inserm Transfert as Investor in Second Fund – AFB Fund II". Paris....
• [7] Hemerion Therapeutics SAS. (4/14/22). "Press Release: Hemerion Therapeutics successfully raises over €3.5 million: a new hope for the treatment of brain cancer". Villeneuve d’Ascq....
• [8] SeaBeLife SAS. (3/14/22). "Press Release: SeaBeLife Receives Close to €1.4M Deep Tech Financing from Bpifrance". Roscoff....
• [9] Cell-Easy. (2/28/22). "Press Release: The OPTI-STEM Consortium Led by CDMO Cell-Easy Receives €7M from the French Government and Bpifrance and €800,000 from the Occitanie Region to Democratize Access to Cell Therapy in France and Europe". Toulouse, La...
• [10] Amolyt Pharma SAS. (2/4/22). "Press Release: Amolyt Pharma Selected for the French Tech 120 Program". Lyon & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.